Healthcare Business Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Business Review
Advanced stem cell therapy clinics provide regenerative treatments using specialized cell-based clinical approaches. With a focus on patient evaluation, treatment oversight, biologic quality and follow-up care, they support safer therapy delivery and more credible regenerative medicine outcomes.
The clinics offer regenerative treatments that harness the unique properties of stem cells to repair, replace, or regenerate damaged tissues and organs. Stem cell therapies show promise across a range of conditions, orthopedic injuries, autoimmune disorders, neurodegenerative diseases, and certain chronic illnesses, offering potential alternatives when traditional treatments fall short.
Across Latin America, advanced stem cell therapies have moved from experimental promise to a growing clinical option for patients who have exhausted conventional interventions. This shift has created a complex decision landscape for healthcare executives evaluating clinical partners, where scientific credibility, patient safety and measurable outcomes must be balanced against a field that still evolves rapidly. The absence of standardized protocols across providers has made differentiation less about access to stem cell technologies and more about how those therapies are applied and monitored over time.
Cellular therapy treatment has been around for 50 years, getting its start with hematopoietic stem cell transplant bone marrow transplant (HSCT) as the treatment of blood cancers. In 2017, a new type of treatment called Chimeric Antigen Receptor T-cell (CAR-T) therapy, has been effective for many patients with far advanced relapsed and refractory blood cancers, and may be used increasingly in the future to supplant BMT. CAR-T uses a patient’s reengineered T-cells to seek and destroy cancer cells in the patient’s body. UPHS, like many other established BMT centers, had to prepare by building the infrastructure to onboard these therapies. Development of a CAR-T therapy infrastructure has created issues that were unique from BMT, including the high dollar cost of the therapy that puts increased risk on centers when delivering this care to patients.
